Deal Library / Pharma BD Deal Intelligence

Pharma Deals of 2019

The Pharma Closeout tracks 69 deals, $330.2B in disclosed deal value, 29 with a post-close Outcome Score for the year 2019.

Median Critic Score: 75  ·  Median Outcome Score: 62

Best outcome: AstraZeneca PLC / Daiichi Sankyo Company, Limited (100)  ·  Weakest outcome: Sanofi SA / Synthorx Inc. (15)

All 69 deals

• AstraZeneca PLC / Daiichi Sankyo Company, Limited — 2019 · $6.9B · Worked — the deal delivered on its rationale.
• Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. — 2019 · $3.3B · Worked — the deal delivered on its rationale.
• Eli Lilly and Company / Loxo Oncology, Inc. — 2019 · $8.0B · Worked — the deal delivered on its rationale.
• Merck & Co. Inc. / Peloton Therapeutics Inc. — 2019 · $2.2B · Worked — the deal delivered on its rationale.
• Vertex Pharmaceuticals Inc. / Semma Therapeutics Inc. — 2019 · $950M · Worked — the deal delivered on its rationale.
• Exact Sciences Corporation / Genomic Health, Inc. — 2019 · $2.8B · Worked — the deal delivered on its rationale.
• Stryker Corporation / Wright Medical Group N.V. — 2019 · $5.4B · Worked — the deal delivered on its rationale.
• Merck KGaA / Versum Materials — 2019 · $5.8B · Worked — the deal delivered on its rationale.
• Bristol-Myers Squibb Company / Celgene Corporation — 2019 · $74.0B · Worked — the deal delivered on its rationale.
• Regeneron Pharmaceuticals, Inc. / Alnylam Pharmaceuticals Inc. — 2019 · $1.0B · Worked — the deal delivered on its rationale.
• Danaher Corporation / GE Life Sciences Biopharma Business (now Cytiva) — 2019 · $21.4B · Worked — the deal delivered on its rationale.
• Pfizer Inc. / Array BioPharma Inc. — 2019 · $11.4B · Largely worked — most objectives met.
• Gilead Sciences Inc. / Nurix Therapeutics Inc. — 2019 · $2.3B · Largely worked — most objectives met.
• Amgen Inc. / Otezla (from Celgene/BMS) — 2019 · $13.4B · Largely worked — most objectives met.
• Roche Holding AG / Sarepta Therapeutics Inc. — 2019 · $1.7B · Largely worked — most objectives met.
• AbbVie Inc. / Allergan, Inc. — 2019 · $63.0B · Largely worked — most objectives met.
• Bayer AG / Arvinas, Inc. — 2019 · $1.0B · Mixed — partial payoff, real shortfalls.
• Merck & Co. Inc. / ArQule Inc. — 2019 · $2.7B · Mixed — partial payoff, real shortfalls.
• Neurocrine Biosciences Inc. / Voyager Therapeutics Inc. — 2019 · $1.9B · Mixed — partial payoff, real shortfalls.
• Merck & Co. Inc. / Seagen Inc. — 2019 · $4.2B · Mixed — partial payoff, real shortfalls.
• Mylan N.V. / Upjohn Inc. (Pfizer) — 2019 · $12.0B · Underwhelmed — fell short of the thesis.
• Novartis AG / Takeda Pharmaceutical Company Ltd. — 2019 · $5.3B · Underwhelmed — fell short of the thesis.
• GlaxoSmithKline plc / Merck KGaA — 2019 · $4.2B · Did not work — the deal failed to deliver.
• GSK plc / Merck KGaA — 2019 · $4.2B · Did not work — the deal failed to deliver.
• Roche Holding AG / Spark Therapeutics Inc. — 2019 · $4.3B · Did not work — the deal failed to deliver.
• Gilead Sciences Inc. / Goldfinch Bio Inc. — 2019 · $240M · Did not work — the deal failed to deliver.
• Gilead Sciences Inc. / Galapagos NV — 2019 · $5.1B · Did not work — the deal failed to deliver.
• Astellas Pharma Inc. / Audentes Therapeutics — 2019 · $3.0B · Did not work — the deal failed to deliver.
• Sanofi SA / Synthorx Inc. — 2019 · $2.5B · Did not work — the deal failed to deliver.
• Astellas Pharma Inc. / Potenza Therapeutics, Inc. — 2019 · $405M
• 3M Company / M*Modal — 2019 · $1.0B
• Biogen Inc. / Nightstar Therapeutics plc — 2019 · $800M
• H. Lundbeck A/S / Alder BioPharmaceuticals, Inc. — 2019 · $1.9B
• Bristol-Myers Squibb Company / Anokion SA / Kanyos Bio Inc. — 2019 · $1.3B
• Thermo Fisher Scientific Inc. / Brammer Bio — 2019 · $1.7B
• Roche Holding AG / Sosei Group Corporation (Sosei Heptares) — 2019 · $1.0B
• Pfizer Inc. / Akcea Therapeutics / Ionis Pharmaceuticals (AKCEA-ANGPTL3-LRx license) — 2019 · $1.3B
• Eli Lilly and Company / AC Immune SA — 2019 · $1.9B
• Boehringer Ingelheim GmbH / AMAL Therapeutics SA — 2019 · $366M
• Eli Lilly and Company / AurKa Pharma Inc. — 2019 · $575M
• Novartis AG / Xiidra (lifitegrast) from Takeda — 2019 · $5.3B
• Ipsen S.A. / Clementia Pharmaceuticals Inc. — 2019 · $1.3B
• Vertex Pharmaceuticals Incorporated / Exonics Therapeutics, Inc. — 2019 · $1.0B
• Novartis AG / IFM Tre, Inc. — 2019 · $1.6B
• UCB S.A. / Ra Pharmaceuticals, Inc. — 2019 · $2.1B
• Royalty Pharma / Biohaven Pharmaceutical Holding Co. Ltd. (rimegepant funding) — 2019 · $200M
• Johnson & Johnson / Auris Health, Inc. — 2019 · $5.8B
• Roche Holding AG / Adaptive Biotechnologies Corporation — 2019 · $2.3B
• Merck & Co. Inc. / Immune Design Corp. — 2019 · $300M
• Boston Scientific Corporation / Vertiflex, Inc. — 2019 · $465M
• Sumitomo Dainippon Pharma Co., Ltd. / Roivant Sciences Ltd. (Sumitovant five-Vant deal) — 2019 · $3.0B
• Pfizer Inc. / Vivet Therapeutics S.A.S. — 2019 · $635M
• Boehringer Ingelheim GmbH / Bridge Biotherapeutics, Inc. — 2019 · $1.2B
• Roche Holding AG / Xencor, Inc. — 2019 · $1.6B
• NJCTTQ (Nanjing CTTQ Pharma) / Abpro Corporation — 2019 · $4.0B
• Roche Holding AG / Skyhawk Therapeutics, Inc. — 2019 · $2.0B
• Alkermes plc / Rodin Therapeutics, Inc. — 2019 · $950M
• Bayer AG / KaNDy Therapeutics Ltd. — 2019 · $875M
• Pfizer Inc. / Therachon Holding AG — 2019 · $810M
• Eli Lilly and Company / Centrexion Therapeutics Corporation — 2019 · $575M
• AbbVie Inc. / Harpoon Therapeutics, Inc. — 2019 · $510M
• Bayer AG / BlueRock Therapeutics LP — 2019 · $600M
• Alexion Pharmaceuticals, Inc. / Achillion Pharmaceuticals, Inc. — 2019 · $1.2B
• Boehringer Ingelheim GmbH / Yuhan Corporation — 2019 · $870M
• Sobi (Swedish Orphan Biovitrum AB) / Dova Pharmaceuticals, Inc. — 2019 · $915M
• Catalent, Inc. / Paragon Bioservices, Inc. — 2019 · $1.2B
• AbbVie Inc. / Boehringer Ingelheim GmbH (Risankizumab buyout) — 2019 · $595M
• Eli Lilly and Company / ImmuNext Inc. (anti-VISTA license) — 2019 · $350M
• Roche Holding AG / Promedior, Inc. — 2019 · $1.4B

← Deal Library  ·  Interactive search  ·  How we score deals